URGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the investor's beginner level, long-term strategy, and available capital, Urogen Pharma Ltd (URGN) is a good buy. The company's positive clinical trial results, improving financial metrics, and hedge fund interest make it a strong candidate for long-term growth, despite the current pre-market dip.
The technical indicators show a bullish trend with MACD positively expanding, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and RSI in a neutral zone (54.089). The stock is trading near the pivot level (20.969) with resistance at 22.134 and support at 19.804.
Strong clinical trial results for ZUSDURI, showing high efficacy and durable responses in bladder cancer patients.
Hedge funds are significantly increasing their positions in the stock (+194.83% last quarter).
Revenue and net income are improving YoY, with EPS showing a 25.45% improvement.
Pre-market price is down by -1.27%, and the broader market (S&P
is also down by -0.84%.
Gross margin dropped slightly (-2.44% YoY).
Stock trend analysis predicts a potential short-term decline of -1.7% in the next day and -4.53% in the next week.
In Q3 2025, revenue increased by 9.04% YoY to $27.48M, net income improved by 40.87% YoY to -$33.35M, and EPS increased by 25.45% YoY to -0.69. However, gross margin slightly declined to 88.07 (-2.44% YoY).
No specific analyst ratings or price target changes provided in the data.
